IP Library › Granted Patent US 9,662,316
Granted Patent B2
US 9,662,316 · App. 15/388,887 · Granted May 30, 2017

Nitrogen-containing heterocyclic compound

Inventors: Masami Yamada (Kanagawa, JP); Shinkichi Suzuki (Kanagawa, JP); Takahiro Sugimoto (Kanagawa, JP); Minoru Nakamura (Kanagawa, JP); Hiroki Sakamoto (Kanagawa, JP); Makoto Kamata (Kanagawa, JP)
Assignee: Takeda Pharmaceutical Company Limited
A61K31/4439
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,662,316
App. No.
15/388,887
Granted
May 30, 2017
Kind
B2
Abstract

The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

Claims (1)

1. A method for the treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia or dementia with Lewy bodies in a mammal, which comprises administering an effective amount of 2-((1S,2S)-2-hydroxycyclohexyl)-4,5-dimethyl-6-((6-methylpyridin-3-yl)methyl)isoindolin-1-one or a salt thereof to the mammal.

Priority Claims (1)
JP 2014-089585 · Apr 23, 2014 · national
Continuity (4)
Continuation 15291769 · Oct 12, 2016
Continuation 15013625 · Feb 2, 2016
Continuation 14693342 · Apr 22, 2015
Related Publication 20170100384A1 · Apr 13, 2017